• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Revenio: Holistic value creation on the horizon

REG1VExtensive research20.03.2023 klo 15.15
Inderes
Discuss
Download report (PDF)

Under the iCare brand, Revenio offers world-class tonometers, fundus imaging devices and perimeters. In recent years, the company has added software solutions to its offering, moving from being an equipment provider to a holistic eye diagnostics solution provider. The core business is growing very profitably, the market has sound growth drivers, and the company’s products have strong competitive advantages. At the same time, the company is creating future growth by developing new growth initiatives, of which Revenio has an excellent track record.

Login required

This content is only available for logged in users

Create account

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more on company page

Key Estimate Figures18.03.2023

202223e24e
Revenue97.0111.4129.6
growth-%23.1 %14.9 %16.3 %
EBIT (adj.)30.934.039.5
EBIT-% (adj.)31.8 %30.5 %30.5 %
EPS (adj.)0.860.981.15
Dividend0.360.420.55
Dividend %0.9 %3.1 %4.1 %
P/E (adj.)44.613.811.8
EV/EBITDA30.69.17.4

Forum discussions

Quite a few new patents this year. E.g. WO2026057923A1 – Air pulse tonometers – published March 19, 2026 WO2026047277A1 – An air pulse based...
yesterday
by TurskaSaavi
2
That seems to be the case. It’s strange that there is so little information available. Nothing really from the manufacturer. Could it be some...
yesterday
by Sissos
0
Could it be an entirely different device, since the identifier is also different from the IC1000?
yesterday
by TurskaSaavi
0
A bit of speculation, but perhaps the USA has been requesting additional studies one after another. Even though the model isn’t specified, my...
yesterday
by Kari
0
Take another look further down the page. The IC100 was approved 10 years ago already.
yesterday
by Sheikki
1
It took a moment to figure out. There was an extra zero there. It was confusing, as the same error was found elsewhere too. So, it is the IC100...
yesterday
by Sissos
0
I am very puzzled by Revenio’s valuation. The multiples of this former growth company have been pushed down to value stock levels. The market...
yesterday
by Tomi Lindell
38